LONDON BROKER RATINGS: Dunelm, AstraZeneca and Persimmon cut
4th Jul 2023 09:27
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday: Read More
(Alliance News) - AstraZeneca PLC on Monday saw shares fall, as test results suggested a new lung cancer drug may be less successful than hoped, despite being generally positive. Read More
(Alliance News) - London's FTSE 100 ran out of steam on Monday to close little changed, while New York markets made a muted start to an abbreviated session ahead of Independence Day. Read More
(Alliance News) - European equities went into Monday afternoon on the up, with the FTSE 100 outperforming as it was supported by its natural resources sector and oil majors. Read More
(Alliance News) - European markets rose at Monday's open, kicking off the start of the second half on a positive note, boosted by strong trading in Asia and New York, Read More
(Alliance News) - AstraZeneca PLC and Tokyo-based partner Daiichi Sankyo Co Ltd on Monday announced that their investigational antibody drug conjugate Datopotamab deruxtecan showed positive results in an advanced non-small cell lung cancer trial. Read More
AstraZeneca PLC - Cambridge-based pharmaceutical company - Announces USD400 million investment in global AZ Forest programme, aiming to plant 50 million trees by the end of 2025 and 200 million trees by 2030. Projects are in Brazil, India, Vietnam, Ghana and Rwanda. The programme is focused on reforestation, biodiversity and community resilience and spans over 100,000 hectares worldwide. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said its Xigduo XR combination treatment has received approval in China for type-2 diabetes. Read More
(Alliance News) - AstraZeneca PLC on Monday said Soliris has been recommended for marketing authorisation in the EU for expanded use in generalised myasthenia gravis, gMG. Read More
(Alliance News) - The Financial Times reported on Monday that AstraZeneca PLC has drafted plans to separate its China business amid geopolitical tensions. Read More
(Alliance News) - Stock prices in London opened lower on Monday, ahead of more interest rate decisions, and amid fears for China's slowing economic recovery. Read More
(Alliance News) - Stocks in London are called lower on Monday, ahead of more central bank decisions, while a meeting between US Secretary of State Antony Blinken and his Chinese counterpart put relations between the two nations back under the spotlight. Read More
(Alliance News) - AstraZeneca PLC has drafted plans to separate its China business amid geopolitical tensions, the Financial Times reported on Monday. Read More
(Alliance News) - Stocks in London are set to open lower on Monday, with a Bank of England decision ahead, and as developments in US-China relations are also in focus. Read More
(Alliance News) - London's FTSE 100 closed higher, though equities in mainland Europe weakened, after both the Federal Reserve and European Central Bank both hinted that they are not done with rate hikes. Read More
(Alliance News) - AstraZeneca PLC on Tuesday announced another approval in China for Soliris to treat a rare neuromuscular disease. Read More
(Alliance News) - AstraZeneca PLC on Monday said its breast cancer drug capivasertib in combination with breast-cancer treating hormone therapy drug faslodex has been granted priority review in the US for patients with advanced HR-positive breast cancer. Read More
(Alliance News) - AstraZeneca PLC on Friday reported positive phase 3 trial data for its oral drug danicopan and struck an agreement with London-based biopharma company Quell Therapeutics Ltd. Read More
(Alliance News) - Stocks in London were called to open higher on Friday, after a weak US jobless claims reading threw "cold water" over expectations for an interest rate hike by the Federal Reserve next week. Read More
(Alliance News) - AstraZeneca PLC on Thursday said that a US Food & Drug Administration committee unanimously recommended its antibody nirsevimab. Read More